Related Experiment Video
Updated: Jul 9, 2026
05:59
High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Light therapy for insomnia in older adults
1Division of Geriatric Medicine, Saint Louis University Health Sciences Center, 1402 S. Grand Boulevard, M238, St. Louis, MO 63104, USA. gammackj@slu.edu
Clinics in Geriatric Medicine
|November 24, 2007
Summary
Bright light therapy helps regulate sleep-wake cycles by suppressing melatonin. For older adults, it may improve sleep and reduce dementia and depression symptoms, though optimal protocols are not yet established.
Area of Science:
- Gerontology
- Sleep Medicine
- Chronobiology
Background:
- Bright light exposure regulates circadian rhythm by suppressing melatonin.
- Older adults often have insufficient daily bright light exposure, impacting sleep-wake cycles.
- Current evidence for bright light therapy (BLT) in the elderly primarily addresses seasonal affective disorder.
Purpose of the Study:
- To review the current understanding and potential applications of bright light therapy for older adults.
- To explore the efficacy of BLT in managing chronic insomnia, dementia, and nonseasonal depression in the elderly.
- To identify gaps in knowledge regarding optimal BLT treatment protocols for geriatric populations.
Main Methods:
- Literature review of studies on bright light therapy and its effects on circadian rhythm, sleep, and cognitive/behavioral symptoms in older adults.
- Analysis of existing evidence for BLT in various geriatric conditions, including insomnia, dementia, and depression.
- Synthesis of findings to discuss potential benefits and challenges of BLT implementation in elderly care.
Main Results:
- Bright light therapy can suppress melatonin and aid circadian rhythm regulation.
- Evidence for BLT in older adults is strongest for seasonal affective disorder, less defined for insomnia, dementia, and depression.
- Potential benefits extend beyond sleep to include reduction of behavioral and cognitive symptoms in dementia and depression.
Conclusions:
- Bright light therapy shows promise for improving sleep and managing behavioral/cognitive symptoms in older adults with insomnia, dementia, and depression.
- Further research is needed to establish optimal treatment protocols for bright light therapy in diverse geriatric conditions.
- BLT may be a valuable non-pharmacological intervention for enhancing the quality of life in the elderly population.
Related Concept Videos
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:27Insomnia
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:23Sedatives and Hypnotics: Overview
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:13Insufficient Sleep and Sleep Deprivation
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...